U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186621) titled 'Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC' on Sept. 16.
Brief Summary: This study is an open-label, randomized controlled, multicenter, phase III clinical trial
Study Start Date: July 10
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Radiotherapy, Adjuvant
Immune Checkpoint Inhibitor
TACE
Narrow Margin
Intervention:
DRUG: Sintilimab
concurrent sintilimab 200mg q3w for 2 cycles followed by maintenance sintilimab 200mg q3w for 15 cycles (approximately 1 year total treatment duration) until disease progression or unacceptable toxicity
RADIATION: radiotherapy
The experimental group will init...